PDT Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.12M | Sell |
683,416
-95,313
| -12% | -$854K | 0.35% | 69 |
|
|
2025
Q1 | $5.84M | Buy |
778,729
+256,439
| +49% | +$1.92M | 0.41% | 45 |
|
|
2024
Q4 | $3.93M | Buy |
522,290
+10
| +0% | +$75 | 0.35% | 78 |
|
|
2024
Q3 | $3.97M | Buy |
522,280
+155,510
| +42% | +$1.18M | 0.35% | 60 |
|
|
2024
Q2 | $2.27M | Sell |
366,770
-13,753
| -4% | -$85K | 0.21% | 173 |
|
|
2024
Q1 | $1.93M | Buy |
380,523
+69,325
| +22% | +$352K | 0.18% | 198 |
|
|
2023
Q4 | $1.86M | Buy |
311,198
+40,489
| +15% | +$243K | 0.21% | 159 |
|
|
2023
Q3 | $1.92M | Buy |
270,709
+71,630
| +36% | +$507K | 0.24% | 138 |
|
|
2023
Q2 | $1.4M | Buy |
199,079
+88,626
| +80% | +$624K | 0.19% | 183 |
|
|
2023
Q1 | $921K | Buy |
110,453
+49,573
| +81% | +$413K | 0.12% | 280 |
|
|
2022
Q4 | $699K | Sell |
60,880
-3,269
| -5% | -$37.5K | 0.11% | 324 |
|
|
2022
Q3 | $808K | Buy |
+64,149
| New | +$808K | 0.12% | 285 |
|
|
2020
Q3 | – | Sell |
-86,518
| Closed | -$412K | – | 724 |
|
|
2020
Q2 | $412K | Buy |
+86,518
| New | +$412K | 0.03% | 455 |
|
|
2017
Q3 | – | Sell |
-129,200
| Closed | -$718K | – | 519 |
|
|
2017
Q2 | $718K | Hold |
129,200
| – | – | 0.03% | 370 |
|
|
2017
Q1 | $1.09M | Sell |
129,200
-1,594
| -1% | -$13.4K | 0.06% | 312 |
|
|
2016
Q4 | $828K | Sell |
130,794
-31,106
| -19% | -$197K | 0.05% | 350 |
|
|
2016
Q3 | $714K | Buy |
+161,900
| New | +$714K | 0.04% | 342 |
|
|
2015
Q3 | – | Sell |
-74,960
| Closed | -$1.12M | – | 1268 |
|
|
2015
Q2 | $1.12M | Buy |
+74,960
| New | +$1.12M | 0.03% | 706 |
|
|
2014
Q4 | – | Sell |
-70,474
| Closed | -$689K | – | 657 |
|
|
2014
Q3 | $689K | Sell |
70,474
-30,040
| -30% | -$294K | 0.02% | 838 |
|
|
2014
Q2 | $1.28M | Buy |
100,514
+60,540
| +151% | +$772K | 0.03% | 607 |
|
|
2014
Q1 | $423K | Sell |
39,974
-51,126
| -56% | -$541K | 0.01% | 1021 |
|
|
2013
Q4 | $692K | Buy |
91,100
+57,043
| +167% | +$433K | 0.08% | 311 |
|
|
2013
Q3 | $248K | Buy |
+34,057
| New | +$248K | 0.01% | 1328 |
|